Pre-exposure prophylaxis for HIV prevention

Truvada, a medication used for PrEP

Pre-exposure prophylaxis (PrEP) is a preventive strategy for individuals who are at high risk of acquiring HIV infection. It involves the use of antiretroviral medications by HIV-negative individuals to reduce their risk of becoming infected with the virus. PrEP is a critical component of comprehensive HIV prevention strategies and has been shown to be highly effective when taken consistently.

Mechanism of Action

PrEP works by maintaining a sufficient level of antiretroviral drugs in the bloodstream to prevent HIV from establishing an infection. The medications used for PrEP interfere with the virus's ability to replicate within the host cells, thereby reducing the likelihood of infection following exposure.

Medications Used for PrEP

The most commonly used medication for PrEP is a combination of tenofovir disoproxil fumarate and emtricitabine, marketed under the brand name Truvada. Another option is a combination of tenofovir alafenamide and emtricitabine, known as Descovy.

A generic version of Truvada

Truvada

Truvada is a fixed-dose combination of two antiretroviral drugs, tenofovir disoproxil fumarate and emtricitabine. It was the first medication approved for use as PrEP and has been widely studied in various populations.

Descovy

Descovy, another medication used for PrEP

Descovy is a newer formulation that includes tenofovir alafenamide, which is associated with fewer side effects related to kidney function and bone density compared to tenofovir disoproxil fumarate.

Efficacy

Clinical trials and real-world studies have demonstrated that PrEP is highly effective in reducing the risk of HIV infection when taken consistently. The level of protection is closely linked to adherence to the medication regimen. Studies have shown that daily use of PrEP can reduce the risk of HIV infection by more than 90% in individuals at high risk.

Eligibility and Guidelines

PrEP is recommended for individuals who are at substantial risk of HIV infection. This includes men who have sex with men, heterosexual individuals with an HIV-positive partner, and people who inject drugs. Guidelines for PrEP use vary by country, but generally include regular HIV testing, monitoring for side effects, and adherence counseling.

Global Access and Availability

Global status of PrEP availability

Access to PrEP varies globally, with some countries having well-established programs and others still in the process of implementing them. Efforts are ongoing to increase the availability and affordability of PrEP, particularly in regions with high rates of HIV infection.

Challenges and Considerations

While PrEP is a powerful tool for HIV prevention, there are challenges associated with its use. These include ensuring adherence to the medication regimen, addressing potential side effects, and overcoming barriers to access such as cost and stigma. Education and outreach are essential to maximize the impact of PrEP.

Related Pages

• HIV/AIDS
• Antiretroviral therapy
• Post-exposure prophylaxis
• Sexually transmitted infection